1stOncology™: Cancer Intelligence Service – Page 12 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

On February 3, 2026 CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, reported that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held February 4-7, 2026, in Salt Lake City, Utah.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx’s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. AlloHeme identifies cancer relapse ahead of traditional detection methods, potentially enabling timely clinical interventions. The ACROBAT study includes patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) monitored with AlloHeme for cancer relapse at 11 hematopoietic stem cell transplant centers across the U.S.

The oral presentation will feature the complete 24-month follow-up results, building upon 18-month interim results published in the conference abstract, available online here.

In addition, on February 12, 2025, CareDx will host an investor webcast and conference call to discuss the study findings and commercial launch timeline.

Tandem Presentation Details:

Presentation ID 61: Acrobat Interim Results: Peripheral Blood-Based AlloHeme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients
Presenter: Dr. Ran Reshef, Professor of Medicine at Columbia University and Director of Translational Research, Blood and Marrow Transplantation Program at Herbert Irving Comprehensive Cancer Center
Date & Time: Friday, February 6, 3:15 p.m. MT
Location: Ballroom I, Salt Palace Convention Center
Investor Webcast Details:

Presentation: AlloHeme Clinical Validation Data Review and Launch Timeline
Date & Time: Thursday, February 12, 7 a.m. PT / 10 a.m. ET
The one-hour event will feature presentations by members of the CareDx’s leadership team and ACROBAT study site Principal Investigator, Dr. Ran Reshef.
A live and archived webcast can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided.

(Press release, CareDx, FEB 3, 2026, View Source [SID1234662443])

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

On February 3, 2026 Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, reported its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).

The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL).

Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at www.tandemmeetings.com.

Details of the Late-Breaking Oral Presentation:

Final Paper Number: LBA-1
Abstract ID & Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Session: Late Breaking Abstracts
Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST
Presenting Author: Naseem Esteghamat, MD MS
About EB103

EB103, a T-cell therapy, also referred to as Estrella’s "CD19-Redirected ARTEMIS T-Cell Therapy," utilizes ARTEMIS technology licensed from Eureka Therapeutics, Inc. ("Eureka"), Estrella’s parent company. Unlike a traditional CAR-T cell, the unique design of an ARTEMIS T-Cell, like EB103 T-cell, allows it to be activated and regulated upon engagement with cancer targets that use a cellular mechanism more closely resembling the one from an endogenous T-cell receptor. Once infused, EB103 T-cells seek out CD19-positive cancer cells, bind to these cells, and destroy them.

(Press release, Estrella Biopharma, FEB 3, 2026, View Source [SID1234662442])

Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

On February 3, 2026 Cycle Group Holdings Limited ("Cycle") reported it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical company.

Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available.

"Cycle was founded with a commitment to support patients living with rare metabolic diseases. From our beginnings with NITYR, we have grown to offer three therapies for this community. With Applied Therapeutics now a part of the Cycle group, we can look to expand further in this area. Our focus remains the same: to bring meaningful, reliable treatments to the patients and families who need them most." says James Harrison, CEO of Cycle.

The transaction is to be funded from cash on hand.

For Cycle, Goodwin Procter LLP acted as legal counsel. For Applied, Aquilo Partners, L.P. provided a fairness opinion, and Ropes & Gray LLP acted as legal counsel.

(Press release, Cycle Pharmaceuticals, FEB 3, 2026, View Source [SID1234662441])

Nucleai Enables Spatial Biology Research in Nature Communications Study on Lung Cancer Treatment Response

On February 3, 2026 Nucleai, a leader in AI-powered multimodal spatial biology, reported its contribution to a collaborative international study published in Nature Communications that explores how spatial organization and metabolic characteristics of tumor cells are associated with response and resistance to immunotherapy in non-small cell lung cancer (NSCLC).

The study, led by academic researchers at The University of Queensland and Yale School of Medicine, applied multiplex immunofluorescence (mIF) and computational approaches to analyze tumor tissue at single-cell resolution. By examining how different cell populations are organized within the tumor microenvironment and how they metabolize glucose, the researchers identified distinct spatial and metabolic patterns associated with immunotherapy outcomes.

As part of the collaboration, Nucleai’s AI-powered multiplex immunofluorescence (mIF) analysis pipeline enabled accurate identification and classification of tumor and immune cell populations at scale, providing a consistent and reproducible foundation for downstream spatial and metabolic analyses conducted by the academic research teams.

"Understanding response to lung cancer treatment requires insight into the different cell states and cell-cell interactions within the tumor, not just which cells and markers are present," said Ettai Markovits, Director of Biomedical Research at Nucleai. "This study highlights the importance of spatial context in cancer biology, and we are pleased to have supported this work by enabling robust, AI-based spatial analysis applied to multiplex imaging data."

Immunotherapy has transformed the treatment landscape for lung cancer, yet only a subset of patients experience durable benefit. Findings from this study suggest that spatially defined metabolic features within tumors may help explain variability in treatment response, reinforcing the need for more nuanced approaches to characterizing tumor biology beyond traditional single-marker assessments.

This work builds on Nucleai’s broader multimodal spatial AI platform, which is designed to support scalable and rapid spatial profiling across large research cohorts. By transforming complex multiplex imaging data into structured, quantitative spatial insights, the platform supports collaborative efforts to advance precision oncology research.

"This study demonstrates the power of multiplex imaging data to shed light on nuanced spatial interactions linked to treatment response to immunotherapy," said Associate Professor Arutha Kulasinghe from UQ’s Frazer Institute. "However, translating this spatial complexity into clinical insights requires sophisticated computational analysis. Nucleai’s contributions helped connect high-dimensional spatial imaging with clinical outcomes more efficiently."

The research was conducted in collaboration with The University of Queensland’s Frazer Institute, Yale School of Medicine, Wesley Research Institute, Quanterix, and Nucleai, and is published in Nature Communications.

(Press release, University of Queensland, FEB 3, 2026, View Source [SID1234662440])

Guardant Health to Participate in Upcoming Investor Conferences

On February 3, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company will be participating in the following investor conferences.

BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
Hosting 1×1 meetings on Tuesday, February 10th
TD Cowen 46th Annual Health Care Conference in Boston, MA
Fireside chat on Wednesday, March 4th at 9:50 a.m. Eastern Time
Leerink Partners Global Health Conference in Miami, FL
Fireside chat on Tuesday, March 10th at 1:00 p.m. Eastern Time
Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL
Fireside chat on Wednesday, March 11th at 1:00 p.m. Eastern Time

Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

(Press release, Guardant Health, FEB 3, 2026, View Source [SID1234662439])